Update: AstraZeneca announced this morning that sunvozertinib is now available in the United States. A major win for the lung cancer community, especially patients with EGFR exon 20 insertion lung cancer who have been waiting for this option.
China approved it in August 2023. The FDA approved it in July 2025. It became commercially available here today. More than three years from its first approval to US availability.
I did not expect this many people to read about my mom. Thank you. If you or someone you love is going through this and doesn’t know where to turn, my messages are open.
https://t.co/yuOkY7a8dp
@AppleBINANCE1 You’re all set. You’ll get a reminder before #WWDC26 starts on June 8 at 10 a.m. PT. Count down to the big day with this curated playlist: https://t.co/bNkyoZhObj
Reply #stop to opt out.